JP2021517129A5 - - Google Patents
Info
- Publication number
- JP2021517129A5 JP2021517129A5 JP2020546926A JP2020546926A JP2021517129A5 JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5 JP 2020546926 A JP2020546926 A JP 2020546926A JP 2020546926 A JP2020546926 A JP 2020546926A JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- cancer
- antibody
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US62/639,587 | 2018-03-07 | ||
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| US62/807,912 | 2019-02-20 | ||
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517129A JP2021517129A (ja) | 2021-07-15 |
| JP2021517129A5 true JP2021517129A5 (https=) | 2022-03-11 |
| JPWO2019171253A5 JPWO2019171253A5 (https=) | 2022-03-11 |
| JP7312188B2 JP7312188B2 (ja) | 2023-07-20 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546926A Active JP7312188B2 (ja) | 2018-03-07 | 2019-03-04 | 抗ｐｄ－１抗体組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (https=) |
| EP (1) | EP3761954A1 (https=) |
| JP (1) | JP7312188B2 (https=) |
| KR (1) | KR102594028B1 (https=) |
| CN (1) | CN112105343B (https=) |
| AU (1) | AU2019232625B2 (https=) |
| BR (1) | BR112020017935A2 (https=) |
| IL (1) | IL277095B2 (https=) |
| MX (1) | MX2020009275A (https=) |
| WO (1) | WO2019171253A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| BR112022007635A2 (pt) * | 2019-11-13 | 2022-07-12 | Pfizer | Formulação aquosa e estável de anticorpos |
| US20230054413A1 (en) * | 2019-12-13 | 2023-02-23 | Samsung Bioepis Co., Ltd. | Stable anti-pd1 antibody pharmaceutical formulations |
| ES3063234T3 (en) | 2019-12-20 | 2026-04-15 | Formycon Ag | Formulations of anti-pd1 antibodies |
| BR112022023989A2 (pt) | 2020-05-26 | 2023-02-07 | Boehringer Ingelheim Int | Anticorpos anti-pd-1 |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| JP2024527517A (ja) * | 2021-06-23 | 2024-07-25 | フォーマイコン アーゲー | 抗ｐｄ１抗体製剤 |
| US20250270316A1 (en) * | 2021-07-01 | 2025-08-28 | Tianjin Lipogen Technology Co., Ltd | Pharmaceutical combination and use thereof |
| US12364756B2 (en) * | 2021-07-09 | 2025-07-22 | Macrogenics, Inc. | Pharmaceutical compositions of a PD-1 antibody and use of the same |
| WO2023031969A1 (en) * | 2021-09-03 | 2023-03-09 | Dr. Reddy’S Laboratories Limited | A method of improving stability of immune check point inhibitors |
| US20240352126A1 (en) * | 2021-09-03 | 2024-10-24 | Dr. Reddy’S Laboratories Limited | A pharmaceutical formulation of immune check point inhibitors |
| IL314840A (en) * | 2022-03-07 | 2024-10-01 | Mabxience Res S L | Stable Antibody Formulations |
| AU2023413756A1 (en) * | 2022-12-21 | 2025-07-10 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
| WO2025036449A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海迈晋生物医药科技有限公司 | 一种包含免疫缀合物的药物组合物及其用途 |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1871806A2 (en) | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| KR20070104673A (ko) * | 2005-03-23 | 2007-10-26 | 화이자 프로덕츠 인코포레이티드 | 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| KR20130066631A (ko) * | 2010-05-06 | 2013-06-20 | 노파르티스 아게 | 치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 다가 항체에 대한 조성물 및 사용 방법 |
| CA2832560A1 (en) * | 2011-04-07 | 2012-10-18 | Glaxosmithkline Llc | Formulations with reduced viscosity |
| MX375378B (es) * | 2013-09-27 | 2025-03-06 | Genentech Inc | Formulaciones de anticuerpos anti-pdl1. |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US10894083B2 (en) * | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
| CA2999079A1 (en) * | 2015-09-28 | 2017-04-06 | Jiangsu Hengrui Medicine Co., Ltd. | Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| CA3063324A1 (en) * | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/pt unknown
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/es unknown
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/zh active Active
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/ko active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517129A5 (https=) | ||
| JP7842070B2 (ja) | 抗ｃｄ３８抗体の皮下製剤及びその使用 | |
| JP2024102215A5 (https=) | ||
| JPWO2019171253A5 (https=) | ||
| JP2020518600A5 (https=) | ||
| JP2021524256A5 (https=) | ||
| RS56210B1 (sr) | Formulacije sa visokom koncentracijom antitela | |
| JP2018503365A5 (https=) | ||
| CN107252485A (zh) | 用于诱导对疾病的免疫应答的组合疗法 | |
| JP2015500207A5 (https=) | ||
| US8992915B2 (en) | Combination of CD37 antibodies with ICE | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| JP7448552B2 (ja) | がんの併用療法 | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| KR20250004789A (ko) | Pd-1 항체를 함유하는 안정한 고농도 아르기닌 제제 및 그의 사용 방법 | |
| CN119584995A (zh) | 组合疗法 | |
| RU2020129226A (ru) | Композиции анти-pd-1 антител | |
| EP4722240A1 (en) | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof | |
| WO2025244529A1 (en) | Dosing regimen of an egfr binding and/or complement activating antibody | |
| HK40126447A (zh) | 抗cd38抗体的皮下制剂及其用途 | |
| WO2025072516A1 (en) | Methods of reducing weight loss using anti-gdf15 antibodies | |
| CN115944741A (zh) | 含TGF-β受体的融合蛋白与紫杉类、核苷类似物联合在制备治疗胰腺癌药物中的用途 | |
| KR20260053090A (ko) | 항-cd38 항체의 피하 제제 및 이의 용도 | |
| KR20260053410A (ko) | 항-cd38 항체의 피하 제제 및 이의 용도 | |
| HK40041199B (zh) | 抗-pd-1抗体组合物 |